Skip to navigation Skip to content

Solid tumours with confirmed NTRK gene fusion Program in Pharmaceutical Benefits Scheme (PBS) 012-22062457

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised larotrectinib for patients with solid tumours with confirmed neurotrophic tropomyosin receptor kinase (NTRK) gene fusion.

Solid tumours with confirmed NTRK gene fusion and listing dates

NTRK gene fusion can result in the development and growth of solid tumours in a variety of tissue types.

Listing date: larotrectinib - 1 July 2022

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • the PBS schedule
  • Service Australia website link

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Written Authority Required Drugs